CN1694954A - Selection and use of lactic acid bacteria for reducing inflammmation caused by helicobacter - Google Patents

Selection and use of lactic acid bacteria for reducing inflammmation caused by helicobacter Download PDF

Info

Publication number
CN1694954A
CN1694954A CNA2003801008000A CN200380100800A CN1694954A CN 1694954 A CN1694954 A CN 1694954A CN A2003801008000 A CNA2003801008000 A CN A2003801008000A CN 200380100800 A CN200380100800 A CN 200380100800A CN 1694954 A CN1694954 A CN 1694954A
Authority
CN
China
Prior art keywords
composition
bacterial strain
cell
helicobacter pylori
atcc pta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2003801008000A
Other languages
Chinese (zh)
Other versions
CN1694954B (en
Inventor
布·莫尔斯泰姆
埃蒙·康诺利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogaia AB
Original Assignee
Biogaia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia AB filed Critical Biogaia AB
Publication of CN1694954A publication Critical patent/CN1694954A/en
Application granted granted Critical
Publication of CN1694954B publication Critical patent/CN1694954B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.

Description

Be used to reduce selection and the application of the milk-acid bacteria that causes inflammation by Helicobacter pylori
Background of invention
Invention field
The present invention relates to be used to screen the application of non-cause of disease anti-inflammatory bacterial strain method and use this class bacterial strain to be used for the treatment of and prevent product and method by the bacterial inflammation of stomach and intestine such as helicobacter pylori, other screw rod bacterial classification and other gastrointestinal disorder substance that causes inflammation.
Prior art
Helicobacter pylori is a kind of volution bacterium, and it is settled down under one's belt, also therein by its ability that produces urase with in and acid in the stomach.Urase conversion of urea (it has abundant supply under one's belt) is supercarbonate and ammonia, and they are highly basic.This will cause existing at the helicobacter pylori cell peripheral the sour neutralization bases of cloud form, not be subjected to the influence of hydrochloric acid in gastric juice to protect them.The helicobacter pylorus mycetocyte infiltrates and passes gastric mucus layer, is attached on the epithelial cell of stomach inner membrance.The helicobacter pylorus bacteria strain of at least a portion has toxigenic ability.The immunity system of helicobacter pylori infection meeting stimulation of host, it can carry white cell, killer T cell and other anti-infection agent to this zone, and still, the human immune system is not effective when the mucus inner membrance of stomach reverses the helicobacter pylori effect.The helicobacter pylorus mycetocyte still is present in this inside, and immunity system progressively strengthens the response of its pair cell, and if there is no useful abundant anti-inflammatory mechanisms will cause inflammation.In the helicobacter pylori infection process,, can propagate the pathogenic agent of immune response to invasion and attack by phytokinin (cytokine) intercellular signal albumen, intrinsic killer cell, T cell and other immune defense cell that host epithelium dendritic produces.Consequently, host's neutrophil attracted to and permeates the epithelial cell of stomach, and remains in this place in whole course of infection.Except other factor, these cells can produce the active oxygen product, and as peroxide radical, they can cause taking place oxidation response and epithelial cell death subsequently, ulceration and final oncogenesis in this epithelial cell.Helicobacter pylori also can be brought out the epithelial cell of nutrient from host's leakage outflow stomach, provide nutrient source to keep helicobacter pylori, and aggravation is infected and its consequence.Helicobacter pylori can be hidden the human immune system, survives in the stomach, although host's immune response and thisly hide the target that mechanism is current research.
Current treatment is based on by microbiotic and proton pump inhibitor and eliminates helicobacter pylori, rather than the influence of the excessive immune response of attempt elimination host to infecting, and for example, makes abundant anti-inflammatory mechanism more effective, and it is a purpose of the present invention.
Therefore, helicobacter pylori infection can cause the danger that developing gastritis, stomach ulcer and duodenal ulcer increase, and comprises the lymphoid tissue lymphoma that stomach ulcer, cancer of the stomach and stomach mucous membrane are relevant.These problems directly do not cause by helicobacter pylori, but cause by the inflammation of stomach inner membrance response helicobacter pylori.Used multiple therapy methods already, be used for improving the symptom of stomach ulcer and duodenal ulcer, for example, combined, and can reduce the methods of treatment that acid produces in the stomach with microbiotic.Novel anti-helicobacter pylori vaccine tried, but only had limited success.Knew already that other helicobacter pylorus bacterial classification and other gastrointestinal disorder substance can cause gastrointestinal inflammation.
Studying in the article recently, the researchist of research helicobacter pylori infection reaches a conclusion, helicobacter pylori infection can cause the part of stomach mucous membrane sialic acid (sialylation) as the chronic inflammatory diseases response, and thereby many virulent strains more can be connected to this inflamed sites (Science18:573-578,2002).
Interior and the GI inflammation of stomach, can be adjusted by the intercellular signal albumen that is called phytokinin, this phytokinin is produced such as the stimulation that is produced by helicobacter pylori or other pathogenic agent by scavenger cell in the epithelial cell and dendritic cell response antigenic stimulation.When contacting when this epithelial cell and antigen such as helicobacter pylori or by the intracellular toxin of its generation such as LPS, antigen presenting cell in this epithelial cell (comprising dendritic cell) can be propagated this signal to the nature scavenger cell, it then responds with so-called Th-1 type, wherein, comprise that TNF α, IL-1, the preceding inflammatory cells mitogen of IL-6, IL-12R are produced by scavenger cell.These phytokinin stimulate intrinsic killer cell, T-cell and other cell to produce interferon-gamma (IFN γ) conversely, and it is the crucial substratum of inflammation.IFN γ can cause inflammatory response and the above-mentioned progressively upgrading that causes cell-cytotoxic reaction.The nature scavenger cell also can respond antigen with the response of Th-2 type.This response is subjected to the inhibition of IFN γ.These Th-2 type cells produce antiphlogistic phytokinin, such as IL-4, IL-5, IL-9 and IL-10.
Known that IL-10 can suppress to produce IFN γ, thereby can suppress immune response.Balance between Th-1 and the Th-2 and they phytokinin separately produce, and have determined the degree for given antigenic inflammatory response.Th-2 type cell can also be via the generation of immunity system immune stimulatory sphaeroprotein.Wherein there is the TNF alpha levels that reduces in anti-inflammatory activity in gi tract, and is relevant with the epithelial cell that improves (film integrality in the intestines wall), thereby, be associated with the negative interaction reduction that causes by gastrointestinal disorder substance and toxin.
The result of big quantity research shows that DNA can bring into play anti-inflammatory action to intestinal epithelial cells, perhaps, and can stimulating immune system.(Madsen etc. and each leisures " digestive ailment periodical (Digestive Disease Week) " such as Rachmilewitz, May 19-22,2002, The MosconeCenter, the statement of San Francisco).
The spontaneous chronic colitis that produces of mouse, this can not take place in virus-free animal.Mouse colitis is similar to people's Crohn disease, and it is a kind of chronic serious gastrointestinal tract inflammation.Crohn disease usually occurs in the intestines, but also can occur in Anywhere GI.These situations all need to exist intestinal microflora, and they all are that Th-1 mesomeric-IL-12-relies on shape colitis.Because the similarity of cause and symptom, the mouse models of colitis and other mouse models are used to directly study the composition of inflammatory response, and, be used for research and development to human intestines and stomach's treatment of diseases to be applied to the same mechanism of human body, to be accepted.
Reuteri is a kind of naturally occurring animal gastrointestinal tract resident, and it is found daily in the intestines of healthy animal, although have low pH, also is present in people's the stomach sometimes.Known it have anti-microbial activity.For example, referring to United States Patent (USP) 5,439,678,5,458,875,5,534,253,5,837,238 and 5,849,289.When the reuteri cell when under anaerobic condition, growing in the presence of the glycerine, they can produce the antimicrobial substance that is called no albumen mycoplasma (reuterin) (beta-hydroxy-propionic aldehyde).
Bar-shaped newborn genus bacillus (Lactobacillus coryniformis) is a kind of lactobacillus species rarely known by the people, and it is the common occupant of human oral cavity.It can be found in soil, fertilizer and plant materials.It has been found that in the silage neutralization when beer degenerates, and good lactic acid-producing and anti-mycotic activity also have report.Bar-shaped newborn genus bacillus MM7 isolate used herein (ATCC PTA-4660) is found to be present in the human mother's milk.
Immunity modulation activity is also relevant with multiple lactobacillus.Although the possibility of effective anti-microbial activity of some lactobacilluss is known,, be present in that they reduce the substantial differences of gastrointestinal inflammatory ability between the bacterial strain, also not known in the past, neither be known to the selection of this class bacterial strain.
Therefore, purpose of the present invention provides lactic bacilli strains, can reduce the gastrointestinal inflammation ability through selecting for them, for example owing to the inflammation of helicobacter pylori.Another object of the present invention provides the product that contains described bacterial strain, comprises being used for the human body administration with treatment or the prevention reagent with the relevant inflammation of helicobacter pylori, comprises conditioned media, and wherein said bacterial strain has grown up to and contained protein extract.
Other purpose and advantage will from following explanation and subsequently claims become more cheer and bright.
Summary of the invention
The present invention includes for reducing the lactic bacilli strains of gastrointestinal inflammation ability through selecting, for example this inflammation is owing to helicobacter pylori, with the product that is derived from described bacterial strain, comprise and be used for the human body administration with treatment or prevention reagent with the relevant inflammation of helicobacter pylori, and comprise that conditioned media, wherein said bacterial strain have grown up to and this conditioned media contain protein extract.
Other purpose of the present invention and feature will from following explanation and subsequently claims become more cheer and bright.
Brief Description Of Drawings
The bar graph that Fig. 1 influences the TNF α that is produced by the LPS activated macrophage for expression lactobacillus conditioned media.45 kinds of lactic bacilli strainss obtain test.
Fig. 2 is illustrated in conditioned media to have the scavenger cell TNF alpha expression of following various different lactobacillus strains and LPS and the bar graph of the scavenger cell that LPS is only arranged folding variation relatively.
Detailed description of the invention and preferred embodiment thereof
The present invention includes for reducing the lactic bacilli strains of gastrointestinal inflammation ability through selecting, for example this inflammation is owing to helicobacter pylori.This class bacterial strain comprises bar-shaped newborn genus bacillus MM7, ATCC PTA-4660 and reuteri MM2-3, ATCC PTA-4659.Such as food, nutritional additive and prescription, pharmaceuticals or contain the product of the medicine equipment of the whole cells that are derived from these bacterial strains or composition, can prepare by means known in the art, generally include known carrier and lactic bacilli strains or its composition of deriving that absorbs.The bacterial strain of previously known confirms that now having good TNF α reduces ability, such as rhamnose lactic acid bacteria GGATCC 53103, reuteri ATCC 55730 and other bacterial strain, also can be used for above-mentioned prescription.These products are to be used for the human body administration with treatment or the prevention reagent with the relevant inflammation of helicobacter pylori.
Use the model system of suitable phytokinin, be used for determining to reduce or to improve the factor of inflammation.In the embodiment that the application provides, a kind of mouse macrophage assay, it uses RAW 264.7 scavenger cell (ATCC, Rockville, MD, ATCC # TIB-71), being used for screen strains of bacteria mainly is lactobacillus, to determine their influences for inflammatory pathway.IL-10 is used for this chemical examination as positive regulation, adopts the treatment of IL-10 inhibited for preceding inflammatory cell mitogen such as TNF α (tumor necrosis factor alpha).After independent cultivation of lactobacillus strains process in the laboratory culture base of screening,, in the scavenger cell chemical examination, supernatant liquor (being also referred to as " conditioned media " among the application) is tested by removing by filter bacterial cell alive.Inflammatory antigen stimulated before scavenger cell adopted earlier, for example, the LPS of purifying (intestinal bacteria deutero-lipopolysaccharides), streptococcus aureus deutero-fat techoic acid (LTA) or do not contain intestinal bacteria or the cell of Helicobacter pylori conditioned media contain the preceding inflammatory cell mitogen of TNF α with generation.Be derived from the conditioned media of lactic bacilli strains, contain the supposition immunity modulation material that is derived from the screening bacterium, cultivated with antigen activatory scavenger cell.Conditioned media can produce by the TNF α that changes this cell and monitor the ability of modulation macrophage immunity response.From the TNF of this chemical examination α profile, can guarantee that the bacterial strain of selecting is being the most effective aspect the TNF α generation that reduces scavenger cell.In this assay system, adopt the control experiment of pH regulator, eliminated the pH that changes and to have caused the possibility of observing influence.
Astoundingly, obvious similar bacterial isolates and lactic bacilli strains, even from closely similar human body source all shows when different ability that change and extensive all influences before response inflammatory antigen the generation by the TNF α of scavenger cell.These bacterial strains even can not be identified by genetic fingerprint are because they can still, still have very different influences for immunocyte up to 98% genetic resemblance.Through this screening and find the strong inhibition effect of bacterial strain have to(for) inflammatory cell mitogen production before preventing being excited of scavenger cell, be very effective for treating the human gastrointestinal tract inflammation, comprise the microbial stomach inflammation of helicobacter pylorus.
Feature of the present invention will become more cheer and bright by means of following embodiment, and still, these embodiment can not be interpreted as it is limitation of the present invention.
Embodiment 1 selects the anti-inflammatory bacterial strain
Lactobacillus [for example, comprise rhamnose lactic acid bacteria GG ATCC 53103, Yue Shi lactobacillus (L.Johnsonii) ATCC 33200, reuteri MM2-3ATCCPTA-4659, bar-shaped newborn Bacillus strain, MM7, ATCC PTA-4660] and intestinal bacteria Nissle, respectively at de Man, Rogosa, (Difco, Sparks MD) cultivate for Sharpe (MRS) and Luria-Bertani (LB) substratum.Spend the night, the lactobacillus culture is diluted to OD 600Be 1.0 (approximately to represent 10 9Cell/ml), further diluted with 1: 10, and cultivated in addition 4,8 and 24 hours.Helicobacter pylori, (sydney strain SS1) and helicobacter hepaticus 381 (ATCC 51449) were cultivated 48 hours in being supplemented with the cloth Lu Shi meat soup (Difco) of 10% fetal bovine serum (FBS).Culture diluted with 1: 10, and cultivated other 24 and 48 hours.4 ℃ in the 8500rpm peripheral speed by centrifugation 10 minutes, collect the conditioned media do not contain bacterial cell.Conditioned media is separated with this cell pellet, then filter flow through 0.22 μ m hole filtration unit (Millipore, Bedford, Mass).
Mouse monocyte/macrophage cell lines, RAW 264.7 (ATCC TIB-71) and RAW 264.7 γ NO (-) (ATCC CRL-2278) are as the report cell of research inflammatory reaction approach.RAW 264.7 cells are to be supplemented with 10%FBS and 2% microbiotic (5000 units/ml penicillin and 5mg/ml Streptomycin sulphate, Sigma) Dulbecco ' s modification hawk substratum (wild-type) or RPMI substratum 1640 (γ NO-) (Gibco-InvitrogenCarlsbad, CA) in 5% CO 2Cultivate under 37 ℃, merge up to 80-90%.About 5 * 10 4Cell is seeded in the 96 porocyte cultures bunch, and before lipopolysaccharides (LPS) activation and adding conditioned media, makes it bonding 2 hours.Nature RAW 264.7 cellular exposure are in the purifying LPS from intestinal bacteria serotype O127:B8 (Sigma).Activation culture is added 2ng LPS by every hole and is carried out to 20 μ l conditioned media.Scavenger cell both can be cultivated in advance, perhaps can cultivate altogether with not celliferous lactobacillus conditioned media.Recombinant chou mIL-10 (R﹠amp; The D system, Minneapolis is Min.) as positive regulation.Cell survival rate is estimated by trypan blue (Invitrogen) eliminating.The existence of TNF-α in cell culture supernatant liquid adopts sandwich enzyme immunoassay to measure, and Quantikine M  mouse TNF-alpha immunization is measured (R﹠amp; The D system).
The lactobacillus conditioned media is to the influence of the TNF-α generation of LPS activated macrophage, and as shown in Figure 1, it shows that in 45 kinds of bacterial strains of test, multiple different strains has the ability of the TNF-α generation that reduces activated macrophage.Fig. 2 represents the folding variation that the TNF alpha expression of various different lactobacillus strains is compared with independent LPS.These results of study then can be used to select the most effective bacterial strain.The bacterial strain of mentioning but not mentioning especially in text is arranged in the accompanying drawings, is that after tested lactobacillus mainly is the various bacterial strains of reuteri.
In this embodiment, bar-shaped newborn genus bacillus MM7, ATCC PTA-4660 selects by using aforesaid method, is used for adding to standard yogurt.By using diary industry to cultivate the standard method of lactobacillus, make bar-shaped newborn Bacillus strain cultivate and make it freeze-drying.This culture then adds in the previous fermented milk, uses traditional yogurt cultures, and with the level of 10E+7CFU/ gram sour milk, this sour milk is behaved used, as preventing by the microbial gastritis of helicobacter pylorus.
Embodiment 2 uses conditioned media
Use aforesaid method, in this embodiment, the conditioned media that is derived from a kind of effective TNF-α reduction bacterial strain is to select to be derived from the substratum of reuteri ATCC PTA-4659.This substratum is by making this bacterial strain at de Man, Rogosa, and (Difco, Sparks MD) cultivate and preparation on a large scale Sharpe (MRS).Spend the night, the lactobacillus culture is diluted to OD 600Be 1.0 (approximately to represent 10 9Cell/ml), further diluted with 1: 10, and cultivated in addition 24 hours.4 ℃ in the 8500rpm rotating speed by centrifugation 10 minutes, collect the conditioned media do not contain bacterial cell.Conditioned media is separated with this cell pellet, then filter flow through 0.22 μ m hole filtration unit (Millipore, Bedford, Mass).This conditioned media is then carried out freeze-drying, and uses standard method to prepare to make tablet.This tablet is used for treatment by the microbial ulcer of helicobacter pylorus by the people as medicine.
The dna fingerprint identification of embodiment 3 reuteri bacterial strains
Use the United States Patent (USP) 5,523,217 and 5,691 of Lupski etc., 136 method is carried out the genome fingerprint recognition of reuteri bacterial strain.The amplification of the DNA of bacteria of the primer of this method utilization by adding a pair of appearance orientation in the bacteria samples.After amplification, the extension products of gained hybridization separates by size, and bacterial isolates characterizes it by measuring fractionated extension products pattern.By using Upriime E primer (a kind of primer), for Bacterial Barcodes, (Houston, 82 kinds of reuteri bacterial strains TX) obtain two times of gel images to Inc..Two times of groups of these data are comparable.Have 11 mutual different bunches and 8 and seem unique outliers.
Having been found that for reducing effectively (referring to Fig. 1 and 2) bacterial strain of TNF-α, make in this way not gather together, show and use dna fingerprint to discern this method to find to have the multiple bacterial strain of TNF-α, is inadequate.
Embodiment 4 characterizes the protein that is produced by effective lactic bacilli strains
Adopt multiple denaturing compounds, different effective lactobacillus conditioned media is comprised the synthetic substratum of reuteri bacterial strain MM2-3, handle, with the character of the supposition immunity modulus of determining to be derived from this bacterium.Like this, conditioned media is carried out the digestion of multiple freeze thawing, thermal treatment, employing DNA digestive ferment, proteolytic enzyme and inactivated proteases.Like this, suppose that immune modulus is confirmed as one or more protein or peptide in fact.In order to determine the size of rich or poor protein immunity modulus, by filtering this conditioned media is separated, and the curative effect of filtrates tested.Like this, find the activeconstituents of the conditioned media of effective lactobacillus, size is about 5kDa or littler.
Although the present invention was illustrated it by embodiment already, but, should be appreciated that multiple variation, improvement and embodiment are possible, therefore, all these variations, improvement and embodiment can be considered to be within the spirit and scope of the invention.

Claims (23)

1, a kind of bar-shaped newborn Bacillus strain MM7, the biological pure culture of ATCC PTA-4660.
2, a kind of reuteri bacterial strain MM2-3, the biological pure culture of ATCC PTA-4659.
3, a kind of biological pure culture of lactic bacilli strains is by using mouse macrophage assay TNF alpha active, having the gastrointestinal inflammatory ability relevant with helicobacter pylori infection in the Mammals gi tract of reduction for it and select.
4, a kind of composition that reduces with the helicobacter pylori related inflammation is derived from the biological pure culture of lactic bacilli strains, and described composition obtains in the never celliferous culture supernatants after described bacterial strain is cultivated, and has the ability that reduces TNF α quantity.
5, the composition of described reduction of claim 4 and helicobacter pylori related inflammation, wherein, described composition is protein or its integral part.
6, the described composition of claim 5, wherein, described protein or its integral part are characterised in that less than 5kDa.
7, a kind of from reuteri bacterial strain MM2-3, the biological pure culture of ATCC PTA-4659 separates the not celliferous culture supernatants that obtains.
8, a kind of from bar-shaped newborn Bacillus strain MM7, the biological pure culture of ATCC PTA-4660 separates the not celliferous culture supernatants that obtains.
9, a kind of food compositions, but the composition that comprises a kind of digested vector and a kind of reduction and helicobacter pylori related inflammation, this composition is derived from a kind of lactic bacilli strains, it is selected from by bar-shaped newborn Bacillus strain MM7, ATCC PTA-4660 and reuteri bacterial strain MM2-3, the group that ATCC PTA-4659 forms.
10, the described food compositions of claim 9, wherein, described composition contains the cell of the biological pure culture of described lactic bacilli strains.
11, a kind of pharmaceutical composition, the composition that comprises a kind of pharmaceutical carrier and a kind of reduction and helicobacter pylori related inflammation, this composition is derived from a kind of lactic bacilli strains, it is selected from by bar-shaped newborn Bacillus strain MM7, ATCC PTA-4660 and reuteri bacterial strain MM2-3, the group that ATCC PTA-4659 forms.
12, the described pharmaceutical composition of claim 11, wherein, described composition contains the cell of the biological pure culture of described lactic bacilli strains.
13, a kind of nutritional supplement, but the composition that comprises a kind of digested vector and a kind of reduction and helicobacter pylori related inflammation, this composition is derived from a kind of lactic bacilli strains, it is selected from by bar-shaped newborn Bacillus strain MM7, ATCC PTA-4660 and reuteri bacterial strain MM2-3, the group that ATCC PTA-4659 forms.
14, the described nutritional supplement of claim 13, wherein, described composition contains the cell of the biological pure culture of described lactic bacilli strains.
15, a kind of method for preparing food compositions comprises:
A. select a kind of lactic bacilli strains of claim 3;
B. obtain a kind of anti-inflammatory component from described bacterial strain; With
But c. add described composition and in a kind of digested vector, obtain food.
16, a kind of method of pharmaceutical compositions comprises:
A. select a kind of lactic bacilli strains of claim 3;
B. obtain a kind of anti-inflammatory component from described bacterial strain; With
C. add described composition and in pharmaceutical carrier, obtain a kind of pharmaceutical composition.
17, a kind of method for preparing nutritional supplement comprises:
A. select a kind of lactic bacilli strains of claim 3;
B. obtain a kind of anti-inflammatory component from described bacterial strain; With
But c. add described composition and in a kind of digested vector, obtain a kind of nutritional supplement.
18, a kind of being used for the treatment of or the reagent of prevention and the relevant inflammation of Helicobacter pylori, contain a kind of anti-inflammatory component that is derived from claim 1,2 or 3 lactic bacilli strains.
19, a kind of being used for the treatment of or the method for prevention and the relevant inflammation of Helicobacter pylori, comprising: select at least a lactic bacilli strains, described at least a bacterial strain is characterized in that it can reduce gastrointestinal inflammation; With with the cell of described at least a bacterial strain to people's administration.
20, the described method of claim 19, wherein, described cell is an oral administration.
21, the described method of claim 19, wherein, described cell is a rectal administration.
22, the described method of claim 19, wherein, described bacterial strain produces a kind of in conditioned media and reduces the active proteins associated matter of inflammatory cell mitogen.
23, the described method of claim 22, wherein, described protein is characterized in that less than 5kDa.
CN2003801008000A 2002-10-07 2003-10-06 Selection and use of lactic acid bacteria for reducing inflammmation caused by helicobacter Expired - Lifetime CN1694954B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/265,859 US7105336B2 (en) 2002-10-07 2002-10-07 Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US10/265,859 2002-10-07
PCT/SE2003/001552 WO2004031368A1 (en) 2002-10-07 2003-10-06 Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter

Publications (2)

Publication Number Publication Date
CN1694954A true CN1694954A (en) 2005-11-09
CN1694954B CN1694954B (en) 2010-05-12

Family

ID=32042542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2003801008000A Expired - Lifetime CN1694954B (en) 2002-10-07 2003-10-06 Selection and use of lactic acid bacteria for reducing inflammmation caused by helicobacter

Country Status (15)

Country Link
US (4) US7105336B2 (en)
EP (1) EP1551952B1 (en)
JP (2) JP4804755B2 (en)
KR (2) KR101107453B1 (en)
CN (1) CN1694954B (en)
AU (1) AU2003269756B2 (en)
BR (1) BR0314511A (en)
DK (1) DK1551952T3 (en)
ES (1) ES2602679T3 (en)
HK (1) HK1079811A1 (en)
HU (1) HUE031627T2 (en)
MX (1) MXPA05003731A (en)
PT (1) PT1551952T (en)
WO (1) WO2004031368A1 (en)
ZA (1) ZA200502602B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102115721B (en) * 2008-05-08 2012-09-26 景岳生物科技股份有限公司 Lactobacillus isolated strains with anti-inflammatory activity and use thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
WO2004034808A1 (en) * 2002-10-18 2004-04-29 Biogaia Ab Method of improving immune function in mammals using lactobacillus reuteri strains
US20050281756A1 (en) 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
WO2005079210A2 (en) * 2003-12-04 2005-09-01 Biofilms Strategies, Inc. Methods and compositions for preventing biofilm formations, reducing existing biofilms, and for reducing existing biofilms, and for reducing populations of bacteria
US7510734B2 (en) * 2004-03-04 2009-03-31 E-L Management Corporation Skin treatment method with Lactobacillus extract
US7955834B2 (en) * 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
EP1703281A1 (en) * 2005-03-16 2006-09-20 Compagnie Gervais Danone Bacteria strain inducing a reduction in the expression of Rbx1
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
DE102005062731A1 (en) 2005-12-22 2007-06-28 Organobalance Gmbh New Lactobacillus strains and their use
US7374924B2 (en) 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
US8603460B2 (en) * 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
WO2008101450A1 (en) * 2007-02-22 2008-08-28 Schrezenmeir Juergen Probiotic, gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in humans
CN101273738B (en) * 2007-03-28 2011-06-01 哈尔滨正方科技有限公司 Method for preparing recombined sour milk drinks having higher viable bacteria at normal temperature
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
KR100886793B1 (en) * 2007-06-26 2009-03-04 한경대학교 산학협력단 Novel Lactobacillus coryniformis HD-02 with antimicrobial and probiotic activity, and its use
RU2556124C2 (en) * 2009-05-11 2015-07-10 Нестек С.А. Lactobacillus johnsonii La1 NCC533 (CNCM 1-1225) AND IMMUNE DISORDERS
US20110293710A1 (en) 2010-02-02 2011-12-01 Delphine Saulnier Immunomodulatory properties of lactobacillus strains
WO2013027087A1 (en) 2011-08-23 2013-02-28 Compagnie Gervais Danone A non-reuterin-producing lactobacillus reuteri strain for treating helicobacter pylori infection
ES2611028T3 (en) * 2011-11-30 2017-05-04 Compagnie Gervais Danone Lactobacillus brevis producer of reuterine
JP2015520773A (en) * 2012-05-29 2015-07-23 ダヌタ・クルセフスカＤａｎｕｔａＫＲＵＳＺＥＷＳＫＡ Nano products containing Lactobacillus reuteri DAN80 useful for prevention and medicine in humans and animals and their pharmaceutical use
US20150284675A1 (en) 2012-10-25 2015-10-08 Compagnie Gervais Danone Streptococcus thermophilus strains for treating helicobacter pylori infection
EP3040412A4 (en) * 2013-08-23 2017-04-05 Consejo Superior De Investigaciones Científicas (CSIC) Probiotic strain of lactobacillus reuteri exhibiting anti-helicobacter activity, a probiotic or biotherapeutic product comprising said strain, and the use thereof
US10799541B2 (en) 2014-07-01 2020-10-13 Probi USA, Inc. Bi-layer dual release probiotic tablets

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5458875A (en) 1990-06-15 1995-10-17 Biogaia Ab In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
ES2111625T3 (en) 1992-07-06 1998-03-16 Nestle Sa ANTIGASTRITIS AGENT.
DE69435303D1 (en) * 1993-05-17 2010-09-02 Cytokine Pharmasciences Inc HE TREATING DISEASES IN WHICH A CYTOK
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US5534253A (en) 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
FI104465B (en) * 1995-06-14 2000-02-15 Valio Oy Protein hydrolyzates for the treatment and prevention of allergies and their preparation and use
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
JP2001514873A (en) * 1997-08-20 2001-09-18 ソーマジェニックス インコーポレイテッド Antisense and antigene therapeutics with improved binding properties and methods of using them
GB9719238D0 (en) * 1997-09-11 1997-11-12 Mathilda & Terence Kennedy Ins Viral infection of cells
MX2008014823A (en) * 1998-02-11 2009-03-06 Neurochem Int Ltd Method for modulating macrophage activation.
EP1085859A4 (en) * 1998-06-11 2003-02-26 Univ New Jersey Med Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
ID29150A (en) * 1999-01-15 2001-08-02 Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
JP4509250B2 (en) * 1999-06-24 2010-07-21 明治乳業株式会社 Helicobacter pylori sanitizing medicine
JP3046303B1 (en) * 1999-06-24 2000-05-29 明治乳業株式会社 Helicobacter pylori eradication food and drink
KR100357668B1 (en) 2000-02-19 2002-10-18 주식회사 한국야쿠르트 Lactobacillus acidophilus HY 2177, Lactobacillus casei HY 2743 having antibiotic activation for Helicobacter pylori and Lactobacillus product thereof
AU4175101A (en) * 2000-02-23 2001-09-03 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
WO2001097821A1 (en) * 2000-06-19 2001-12-27 Mucoprotec Pty Ltd Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
FI109602B (en) * 2001-01-25 2002-09-13 Valio Oy Probiotkombination
US20040241149A1 (en) * 2001-09-05 2004-12-02 Claudio De Simone Use of unmethylatd cpg
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US6872565B2 (en) * 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
WO2004069156A2 (en) * 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102115721B (en) * 2008-05-08 2012-09-26 景岳生物科技股份有限公司 Lactobacillus isolated strains with anti-inflammatory activity and use thereof

Also Published As

Publication number Publication date
KR101107453B1 (en) 2012-01-19
EP1551952A1 (en) 2005-07-13
ZA200502602B (en) 2006-06-28
DK1551952T3 (en) 2016-12-12
PT1551952T (en) 2016-11-23
EP1551952B1 (en) 2016-08-17
JP2006501823A (en) 2006-01-19
US20090110670A1 (en) 2009-04-30
KR101064058B1 (en) 2011-09-08
AU2003269756B2 (en) 2007-08-09
KR20050047107A (en) 2005-05-19
JP5439315B2 (en) 2014-03-12
CN1694954B (en) 2010-05-12
JP2011021015A (en) 2011-02-03
WO2004031368A1 (en) 2004-04-15
ES2602679T3 (en) 2017-02-22
US7105336B2 (en) 2006-09-12
JP4804755B2 (en) 2011-11-02
BR0314511A (en) 2005-08-09
KR20110033943A (en) 2011-04-01
MXPA05003731A (en) 2005-06-17
US20060251636A1 (en) 2006-11-09
HUE031627T2 (en) 2017-09-28
AU2003269756A1 (en) 2004-04-23
US20040067573A1 (en) 2004-04-08
US7678553B2 (en) 2010-03-16
HK1079811A1 (en) 2006-04-13
US7960137B2 (en) 2011-06-14
US20100129337A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
CN1694954B (en) Selection and use of lactic acid bacteria for reducing inflammmation caused by helicobacter
US11760970B2 (en) Lactobacillus plantarum and composition comprising the same
US7901926B2 (en) Lactobacillus isolates having anti-inflammatory activities and uses of the same
TWI422681B (en) Cultivation of lactobacillus with high immune regulating activity
EP1816190B1 (en) New lactic bacteria useful as probiotics
JP5337535B2 (en) NK activity enhancer
Kim et al. Induction of cytokines and nitric oxide in murine macrophages stimulated with enzymatically digested lactobacillus strains
KR20180110848A (en) A novel Lactobacillus reuteri BM36301 and a Probiotic Benefits of the same
Zuo et al. Separation of growth-stimulating peptides for Bifidobacterium from soybean conglycinin
Li et al. The analysis of the impacting factors of probiotics on immune responses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079811

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1079811

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20100512